Table 3.

Biologic Drugs Under Study

Generic name	Brand name	Target	Date of approval	Administration	Typical frequency of dispensing, days
Etanercept	Enbrel	TNF-α*	11/98	Injection	7 days**
Infliximab	Remicade	TNF-α	11/99	Infusion	56 days
Anakinra	Kineret	IL-1 receptor	11/01	Injection	Daily
Adalimumab	Humira	TNF-α	12/02	Injection	14 days**
Alefacept	Amevive	CD2	02/03	Injection	Weekly for 12 weeks, then as needed
Efalizamab**	Raptiva	CD11a	10/03	Injection	Weekly
Abatacept	Orencia	T cell	12/05	Infusion	28 days
Rituximab	Rituxan	CD20+ B cells	3/06	Infusion	14 days (2nd dose), then 6–12 months

^*Tumor necrosis factor-α,.

^**Withdrawn from U.S. in June 2009.